Valuation: Codexis, Inc.

Market Cap 194M 169M 156M 145M 272M 18.6B 277M 1.87B 732M 9.11B 727M 711M 31.36B P/E 2026 *
-5.51x
P/E 2027 * -7.4x
Enterprise Value 194M 169M 156M 145M 272M 18.6B 277M 1.87B 732M 9.11B 727M 711M 31.36B EV / Sales 2026 *
2.61x
EV / Sales 2027 * 2.18x
Free-Float
92.59%
Yield 2026 *
-
Yield 2027 * -
1 day+2.11%
1 week-18.08%
Current month-5.75%
1 month-11.25%
3 months-10.13%
6 months+19.66%
Current year+30.67%
1 week 2.12
Extreme 2.12
2.66
1 month 2.12
Extreme 2.12
2.7
Current year 0.96
Extreme 0.9583
2.98
1 year 0.96
Extreme 0.9583
3.87
3 years 0.96
Extreme 0.9583
6.08
5 years 0.96
Extreme 0.9583
42.01
10 years 0.96
Extreme 0.9583
42.01
Manager TitleAgeSince
Chief Executive Officer 59 07/11/2025
Director of Finance/CFO 59 30/09/2024
Chief Tech/Sci/R&D Officer 56 05/05/2020
Director TitleAgeSince
Director/Board Member 66 01/03/2016
Director/Board Member 59 07/11/2025
Chairman 66 -
Date Insider Type Main position Quantity % Market Cap.
06-17Free

Director

66,350 0.0730%
06-17Free

Director

66,350 0.0730%
06-17Free

Director

66,350 0.0730%
Change 5-day change 1-year change 3-year change Capi.($)
+2.11%-18.08%-30.62%-32.17% 194M
-0.79%+0.91%+2.59%+6.84% 50.35B
-1.02%-2.88%+382.07%+593.81% 39.32B
+0.94%-0.19%+29.79%-6.00% 34.69B
+1.68%-0.78%+21.58%+56.15% 34.08B
-1.31%-3.03%+2.51%+25.24% 26.63B
-0.15%-0.52% - - 16.49B
+0.01%-1.85%+67.36%+120.46% 15.31B
+0.58%+3.49%+15.13%+18.15% 13.8B
+0.68%-0.44%+12.34%-31.79% 12.87B
Average +0.36%-2.55%+55.86%+83.41% 24.37B
Weighted average by Cap. +0.02%-0.74%+80.90%+122.13%

Financials

2026 *2027 *
Net sales 74.1M 64.75M 59.86M 55.3M 104M 7.12B 106M 714M 280M 3.49B 278M 272M 12B 88.93M 77.71M 71.84M 66.37M 125M 8.54B 127M 857M 336M 4.18B 334M 327M 14.4B
Net income -35.29M -30.84M -28.51M -26.34M -49.6M -3.39B -50.5M -340M -133M -1.66B -133M -130M -5.72B -26.56M -23.21M -21.45M -19.82M -37.33M -2.55B -38M -256M -100M -1.25B -99.76M -97.55M -4.3B
Net Debt - -
Logo Codexis, Inc.
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Employees
146
Date Price Change Volume
15/07/26 $2.130 -5.33% 925,698
13/07/26 $2.250 -7.41% 579,667
10/07/26 $2.430 -5.08% 550,515
09/07/26 $2.560 -1.54% 494,152
08/07/26 $2.600 0.00% 536,290
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.130USD
Average target price
6.583USD
Spread / Average Target
+209.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CDXS Stock